TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search
PRESS RELEASES

Magenta Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

Magenta Therapeutics And Bluebird Bio Announce A Phase 2 Clinical Trial Collaboration To Evaluate Magenta's MGTA-145 For Mobilizing And Collecting Stem Cells In Adults And Adolescents With Sickle Cell Disease

PRESS RELEASES

Magenta Therapeutics Appoints Steve Mahoney As Chief Financial And Operating Officer

PRESS RELEASES

Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio At The American Society Of Hematology (ASH) Annual Meeting

PRESS RELEASES

Magenta Therapeutics To Participate In Upcoming Healthcare Investor Conferences In September

PRESS RELEASES

Magenta Therapeutics Named Co-Recipient Of Grant From The National Institutes Of Health To Explore Use Of Novel Targeted Conditioning Agents With Gene Editing Approaches To Cure HIV

PRESS RELEASES

Magenta Therapeutics Appoints Lisa M. Olson As Chief Scientific Officer And Kevin B. Johnson As Senior Vice President, Head Of Regulatory And Quality; Announces Transition Of Jason Ryan, Chief Operating And Financial Officer

PRESS RELEASES

Magenta Therapeutics Announced It Will Present Clinical And Pre-Clinical Data From Across Immune And Blood System Reset Portfolio At European Society For Blood And Marrow Transplantation (EBMT) Annual Meeting

PRESS RELEASES

Magenta Therapeutics To Participate In Upcoming Healthcare Investor Conferences In August

PRESS RELEASES

Magenta Therapeutics Announces Pricing Of Public Offering

PRESS RELEASES

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Magenta Therapeutics, Inc. - MGTA

PRESS RELEASES

Magenta Therapeutics Launches Proposed Public Offering

PRESS RELEASES

MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Magenta Therapeutics, Inc. And Encourages Investors To Contact The Firm

PRESS RELEASES

Magenta Therapeutics And Beam Therapeutics Announce Collaboration To Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 As Conditioning Regimen For Base Editing Therapies

PRESS RELEASES

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization And Conditioning Programs Prioritized And Advancing Toward Clinical Milestones

PRESS RELEASES

Magenta Therapeutics Announces Collaboration With The National Marrow Donor Program/Be The Match To Advance Development Of MGTA-145 For First-Line Mobilization Of Stem Cells From Healthy Donors And Subsequent Patient Transplant

PRESS RELEASES

Magenta Therapeutics To Participate In Upcoming Healthcare Investor Conferences

PRESS RELEASES

Magenta Therapeutics Presents Data Supporting Immune Reset For Autoimmune Diseases

PRESS RELEASES

AVROBIO And Magenta Therapeutics Announce Collaboration To Evaluate Targeted Antibody-Drug Conjugate As A Potential Conditioning Regimen For Lentiviral Gene Therapies

PRESS RELEASES

Magenta Therapeutics And AVROBIO Announce Collaboration To Evaluate Targeted Antibody-Drug Conjugate As A Potential Conditioning Regimen For Lentiviral Gene Therapies

PRESS RELEASES

Magenta Therapeutics To Host Business Update Conference Call

PRESS RELEASES

Magenta Therapeutics To Present Data From Across Portfolio At American Society Of Gene And Cell Therapy (ASGCT) Annual Meeting

PRESS RELEASES

Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head Of Research And Development

PRESS RELEASES

Magenta Therapeutics Provides Business Update